Expand all sections

Ipilimumab

Yervoy

Extended indication

Extension of indication to include in combination with nivolumab the treatment of adolescents (12 ye

Therapeutic value

No estimate possible yet
Registration phase

Registration application pending

Product

Active substance

Ipilimumab
Domain

Oncology
Reason of inclusion

Indication extension
Main indication

Skin cancer
Extended indication

Extension of indication to include in combination with nivolumab the treatment of adolescents (12 years of age and older) for advanced (unresectable or metastatic) melanoma.
Proprietary name

Yervoy
Manufacturer

BMS
Route of administration

Intravenous
Therapeutical formulation

Intravenous drip
Budgetting framework

Intermural (MSZ)

Registration

Registration route

Centralised (EMA)
Type of trajectory

Normal trajectory
ATMP

No
Submission date

September 2022
Expected Registration

July 2023
Orphan drug

No
Registration phase

Registration application pending

Therapeutic value

Therapeutic value

No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.